Bristol-Myers Squibb Co (BMY) : Crossvault Capital Management reduced its stake in Bristol-Myers Squibb Co by 3.48% during the most recent quarter end. The investment management company now holds a total of 111,927 shares of Bristol-Myers Squibb Co which is valued at $7,911,000 after selling 4,040 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Apr 19, 2016.Bristol-Myers Squibb Co makes up approximately 5.75% of Crossvault Capital Management’s portfolio.
Bristol-Myers Squibb Co opened for trading at $70.25 and hit $71.07 on the upside on Friday, eventually ending the session at $70.68, with a gain of 0.74% or 0.52 points. The heightened volatility saw the trading volume jump to 58,03,996 shares. Company has a market cap of $117,997 M.
Other Hedge Funds, Including , First Citizens Bank Trust Co reduced its stake in BMY by selling 1,164 shares or 3.25% in the most recent quarter. The Hedge Fund company now holds 34,691 shares of BMY which is valued at $2,451,960. Bristol-Myers Squibb Co makes up approx 0.20% of First Citizens Bank Trust Co’s portfolio.Horizon Kinetics boosted its stake in BMY in the latest quarter, The investment management firm added 1,334 additional shares and now holds a total of 58,876 shares of Bristol-Myers Squibb Co which is valued at $4,006,512. Bristol-Myers Squibb Co makes up approx 0.10% of Horizon Kinetics’s portfolio. Gavekal Capital sold out all of its stake in BMY during the most recent quarter. The investment firm sold 153,399 shares of BMY which is valued $10,438,802.Central Trust Co boosted its stake in BMY in the latest quarter, The investment management firm added 949 additional shares and now holds a total of 180,734 shares of Bristol-Myers Squibb Co which is valued at $12,298,949. Bristol-Myers Squibb Co makes up approx 0.96% of Central Trust Co’s portfolio. Pensionfund Sabic added BMY to its portfolio by purchasing 45,000 company shares during the most recent quarter which is valued at $2,969,100. Bristol-Myers Squibb Co makes up approx 0.91% of Pensionfund Sabic’s portfolio.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.Bristol-Myers Squibb Co was Upgraded by Berenberg to ” Buy” on Jan 22, 2016.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.